scholarly journals Metagenomic Analysis of Serum Microbe-Derived Extracellular Vesicles and Diagnostic Models to Differentiate Ovarian Cancer and Benign Ovarian Tumor

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1309 ◽  
Author(s):  
Se Ik Kim ◽  
Nayeon Kang ◽  
Sangseob Leem ◽  
Jinho Yang ◽  
HyunA Jo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Vesicles ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Metagenomic Analysis ◽  
Serum Samples ◽  
Benign Ovarian Tumor ◽  
Diagnostic Models ◽  
Test Sets ◽  
Benign Ovarian Tumors

We aimed to develop a diagnostic model identifying ovarian cancer (OC) from benign ovarian tumors using metagenomic data from serum microbe-derived extracellular vesicles (EVs). We obtained serum samples from 166 patients with pathologically confirmed OC and 76 patients with benign ovarian tumors. For model construction and validation, samples were randomly divided into training and test sets in the ratio 2:1. Isolation of microbial EVs from serum samples of the patients and 16S rDNA amplicon sequencing were carried out. Metagenomic and clinicopathologic data-based OC diagnostic models were constructed in the training set and then validated in the test set. There were significant differences in the metagenomic profiles between the OC and benign ovarian tumor groups; specifically, genus Acinetobacter was significantly more abundant in the OC group. More importantly, Acinetobacter was the only common genus identified by seven different statistical analysis methods. Among the various metagenomic and clinicopathologic data-based OC diagnostic models, the model consisting of age, serum CA-125 levels, and relative abundance of Acinetobacter showed the best diagnostic performance with the area under the receiver operating characteristic curve of 0.898 and 0.846 in the training and test sets, respectively. Thus, our findings establish a metagenomic analysis of serum microbe-derived EVs as a potential tool for the diagnosis of OC.

Gonadotropin Levels in Ovarian Cyst Fluids: A Predictor of Malignancy?

1998 ◽  
Vol 13 (3) ◽  
pp. 165-168 ◽  
Author(s):  
S. Krämer ◽  
M. Leeker ◽  
W. Jäger
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Serum Levels ◽  
Ovarian Tumors ◽  
Surgical Removal ◽  
Serum Samples ◽  
Benign Ovarian Tumors ◽  
Surprising Finding ◽  
Cyst Fluids

Gonadotropins can stimulate ovarian cancer growth in cell cultures. Corresponding LH/hCG receptors have been demonstrated in ovarian cancer. However, reduction of elevated serum gonadotropins by GnRH analogs in ovarian cancer patients did not lead to growth restriction, which means that serum levels of gonadotropins may not play the most important role in ovarian cancer. We therefore analyzed the LH and FSH concentrations in cyst fluids of ovarian cancer. Patients with preoperatively diagnosed cystic ovarian tumors were eligible for the study. Serum samples of the patients were obtained during surgery, while the fluids within the cysts were aspirated after surgical removal of the tumor. FSH and LH levels in serum and cyst fluids were measured using single antibody EIA (Boehringer Mannheim GmbH, Germany). Cyst fluids and sera of 108 patients were evaluated. While there were no significant differences in the FSH and LH serum concentrations, highly significant differences in the FSH and LH levels in cyst fluids were found. Only cancer cysts contained FSH and LH, while the corresponding concentrations in benign cysts were always below the measuring range of the assays. This clear division between high gonadotropin levels in cysts of serous ovarian cancer and low or absent concentrations in benign ovarian tumors further supports the hypothesis that FSH and LH may play a role in ovarian cancer; however, explanations for this surprising finding are still lacking.

scholarly journals Morphology of the epoophoron in women with benign ovarian tumor

2011 ◽  
Vol 10 (2) ◽  
pp. 30-32
Author(s):  
L. I. Kokh ◽  
V. M. Perelmuter ◽  
A. V. Tardaskina ◽  
T. N. Dorosh
Keyword(s):  
Ovarian Tumor ◽  
Specific Area ◽  
Ovarian Tumors ◽  
Benign Ovarian Tumor ◽  
Inner Diameter ◽  
Benign Ovarian Tumors

We studied the epoophoron in women with benign ovarian tumor using morphological methods. It was established that the structure epoophoron in women with benign ovarian tumors, there are significant differences compared with controls. This manifests itself in reducing the number of tubules, increase in their specific area, outer and inner diameter, the height of the epithelium, the presence of secretions in the lumen.

scholarly journals Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer

2019 ◽  
Vol 6 (2) ◽  
pp. 12
Author(s):  
Shuna S ◽  
Ping L ◽  
Junfei W
Keyword(s):  
Ovarian Cancer ◽  
Matrix Metalloproteinase ◽  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Expression Levels ◽  
Benign Ovarian Tumor ◽  
Significant Difference ◽  
Malignant Ovarian Tumor ◽  
Serum Ca125 ◽  
The Difference

Objective: To explore the expression levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods: ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor, and RIA was used to detect the expression level of CA125 in the serum in these patients.Results: The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor (t = 8.08, 10.39, p < .01), and the difference was of statistical significance. The expression levels of MMP-2 and MMP-9 in patients with stage III and IV malignant ovarian tumors were higher than those in patients with stage I and II malignant ovarian tumors, and the difference was statistically significant (t = 2.75, 2.75, p < .05). There was no statistically significant difference in the expression levels of MMP-2 and MMP-9 among the patients with different pathological types, different histological grades, lymph node metastasis or not, different ascites volumes and different residual lesions (p > .05). The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0% and 88.0%, respectively, which were significantly higher than those of ascites cytological examinations (χ2 = 4.61, 12.74, p < .05), but in comparison with serum CA125, there was no statistically significant difference (p > .05). The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3% and 82.6%, respectively, which were significantly lower than those of ascites cytological examinations (χ2 = 5.61, 4.38, p < .05), but in comparison with serum CA125, there was no statistically significant difference (χ2 = 1.64, 2.68, p < .05).Conclusions: The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions, and they are related to the prognosis in patients with malignant ovarian tumors.

scholarly journals Telomerase Expression Increased the Risk of Borderline Ovarian Tumors

2016 ◽  
Author(s):  
Mila Maidarti
Keyword(s):  
Odds Ratio ◽  
Immunohistochemical Staining ◽  
Ovarian Tumor ◽  
Obstet Gynecol ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Borderline Ovarian Tumors ◽  
Benign Ovarian Tumor ◽  
Benign Ovarian Tumors

Objective: To compare the expression of telomerase in benign ovarian tumors and borderline ovarian tumors. Methods: Thirteen samples of paraffin blocks of ovarian borderline tumors and benign ovarian tumors were taken from patients who underwent surgery from January 2006 to December 2011. In all samples, we performed immunohistochemical staining to the paraffin blocks. Semi quantitative determination of the expression of telomerase is done by an Anatomic Pathology specialist and Gynecologist, which already had the same perception about assessing the standardization sample. We used Fisher’s test to analyze the data. Results: There were significant relationship in the moderate expression of telomerase in the nucleus and cytoplasm between benign and borderline ovarian tumors, with an odds ratio of moderate telomerase expression in the cytoplasm and nucleus of 19.3 (95% CI: 1.4 - 943) and 26 (95% CI : 2.3 - 1211). This means that the risk of borderline ovarian tumors in the expression of moderate telomerase in the cytoplasm was 3.19 times compared to the negative expression, whereas in the nucleus it became 26-fold. There is no significant relationship among menopause, age, and telomerase expression in the nucleus and cytoplasm. Conclusion: There are significant differences in the expression of moderate strength telomerase in nucleus and cytoplasm between benign and borderline ovarian tumors. [Indones J Obstet Gynecol 2013; 37-1: 32-40] Keywords: benign ovarian tumor, borderline ovarian tumor, telomerase expression

scholarly journals HE4 has a High Diagnostic Value to Detect Epithelial Ovarian Cancer

2016 ◽  
Author(s):  
Bismarck J. Laihad
Keyword(s):  
Ovarian Tumor ◽  
Histopathological Examination ◽  
Diagnostic Value ◽  
Ovarian Tumors ◽  
Diagnostic Study ◽  
Serum Concentrations ◽  
Serum Samples ◽  
Cross Sectional ◽  
Benign Ovarian Tumor ◽  
Tissue Specimens

Objective: To find out the diagnostic value of CA125 and HE4 as a tumor marker, and also RMI and ROMA as a malignancy predictor in patients with ovarian tumors. Methods: This study was a diagnostic study using cross-sectional design.This study was performed in Jakarta from November 2010 to May 2011. One hundred and twenty eight serum samples of patients diagnosed with ovarian tumors were collected before undergoing surgery in Dr. Cipto Mangunkusumo General Hospital. The CA125 and HE4 levels were then examined. The histopathological examination of tissue specimens were performed in Department of Pathology Anatomy in RSCM. For statistical analysis, we used a 2x2 table to produce ROC-AUC curve. Results: The median value of HE4 and CA125 serum concentrations was higher and more significant on patients with ovarian malignancy than patients with benign ovarian tumor (p

Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study

2019 ◽  
Vol 31 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Sonia Guleria ◽  
Allan Jensen ◽  
Anita Toender ◽  
Susanne K. Kjaer
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumors ◽  
Follow Up Study ◽  
Benign Ovarian Tumors

scholarly journals Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Shuang Zhang ◽  
Shan Yu ◽  
Wenying Hou ◽  
Xiaoying Li ◽  
Chunping Ning ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Menopausal Status ◽  
Area Under The Curve ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumor ◽  
Cancer Antigen 125 ◽  
Borderline Ovarian Tumors ◽  
Risk Of Malignancy ◽  
Risk Of Malignancy Index ◽  
Benign Ovarian Tumors

Abstract Background This study aimed to examine the performance of the four risk of malignancy index (RMI) in discriminating borderline ovarian tumors (BOTs) and benign ovarian masses in daily clinical practice. Methods A total of 162 women with BOTs and 379 women with benign ovarian tumors diagnosed at the Second Affiliated Hospital of Harbin Medical University from January 2012 to December 2016 were enrolled in this retrospective study. Also, we classified these patients into serous borderline ovarian tumor (SBOT) and mucinous borderline ovarian tumor (MBOT) subgroup. Preoperative ultrasound findings, cancer antigen 125 (CA125) and menopausal status were reviewed. The area under the curve (AUC) of receiver operator characteristic curves (ROC) and performance indices of RMI I, RMI II, RMI III and RMI IV were calculated and compared for discrimination between benign ovarian tumors and BOTs. Results RMI I had the highest AUC (0.825, 95% CI: 0.790–0.856) among the four RMIs in BOTs group. Similar results were found in SBOT (0.839, 95% CI: 0.804–0.871) and MBOT (0.791, 95% CI: 0.749–0.829) subgroups. RMI I had the highest specificity among the BOTs group (87.6, 95% CI: 83.9–90.7%), SBOT (87.6, 95% CI: 83.9–90.7%) and MBOT group (87.6, 95% CI: 83.9–90.7%). RMI II scored the highest overall in terms of sensitivity among the BOTs group (69.75, 95% CI: 62.1–76.7%), SBOT (74.34, 95% CI: 65.3–82.1%) and MBOT (59.18, 95% CI: 44.2–73.0%) group. Conclusion Compared to other RMIs, RMI I was the best-performed method for differentiation of BOTs from benign ovarian tumors. At the same time, RMI I also performed best in the discrimination SBOT from benign ovarian tumors.

scholarly journals Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study

2020 ◽  
Vol Volume 12 ◽  
pp. 637-649 ◽  
Author(s):  
Chen-Yu Huang ◽  
Wen-Hsun Chang ◽  
Hsin-Yi Huang ◽  
Chao-Yu Guo ◽  
Yiing-Jenq Chou ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cohort Study ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Tumor ◽  
Subsequent Development ◽  
Population Based ◽  
Benign Ovarian Tumor ◽  
Ovarian Surgery

Obstetrics and Gynecology Residents Can Accurately Classify Benign Ovarian Tumors Using the International Ovarian Tumor Analysis Rules

2020 ◽  
Vol 39 (7) ◽  
pp. 1389-1393
Author(s):  
Jean Marie Vianney Sebajuri ◽  
Urania Magriples ◽  
Maria Small ◽  
Diomede Ntasumbumuyange ◽  
Stephen Rulisa ◽  
...  
Keyword(s):  
Ovarian Tumor ◽  
Ovarian Tumors ◽  
Obstetrics And Gynecology ◽  
Benign Ovarian Tumors

FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary.

2004 ◽  
Vol 11 (2) ◽  
pp. 315-321 ◽  
Author(s):  
I Rzepka-G√≥rska ◽  
A Chudecka-G≈Çaz ◽  
B Kosmowska
Keyword(s):  
Ovarian Cancer ◽  
Differential Diagnosis ◽  
Malignant Tumors ◽  
Ovarian Tumors ◽  
Predictive Values ◽  
Epithelial Tumors ◽  
Ovarian Carcinogenesis ◽  
Benign Ovarian Tumors ◽  
Sensitivity Specificity

The aim of this work was to compare mean concentrations of gonadotropins in serum and fluid from malignant and benign ovarian tumors. We enrolled 126 patients diagnosed with malignant epithelial tumors (n=40), borderline epithelial tumors (n=14), benign cystadenomas (n=28) and simple cysts (n=44) of the ovary. Premenopausal and postmenopausal subgroups were formed in each group. The concentration of FSH and LH was measured in serum and tumor fluid and the serum/tumor fluid ratio was calculated. The results in each group were compared and the sensitivity, specificity, positive and negative predictive values were determined. Mean concentrations of both gonadotropins in ovarian cancer fluid were significantly higher than in the remaining groups (P ranged from <0.005 to <0.0001). Mean serum/fluid ratios were lowest in ovarian cancer (FSH=2.91, LH=4.19). Our findings support the hypothesis that gonadotropins are involved in ovarian carcinogenesis and suggest that gonadotropin serum/tumor fluid ratios could be of value in the differential diagnosis of functional and organic cysts of the ovary.

Sign in / Sign up

Export Citation Format

Share Document